Lymphoma, Large-Cell, Diffuse
Conditions
Brief summary
This trial was a prospective, multicenter, randomized, controlled Phase III clinical design to compare the efficacy and safety of decitabine combined with R-CHOP (R-CHOP-D) versus R-CHOP in the treatment of primary EBV+ diffuse large B-cell lymphoma (DLBCL). Sixty patients were randomized 1:1 into R-CHOP-D (trial group) or R-CHOP (control group). The trial consisted of a screening period (days -28 to -1), a treatment period, and a follow-up period (2 years after the end of the last trial).
Interventions
DRUGR-CHOP
Decitabine in combination with R-CHOP
DRUGDecitabine in combination with R-CHOP
Decitabine in combination with R-CHOP
Sponsors
Second Affiliated Hospital of Nanchang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Initial treatment of diffuse large B-cell lymphoma (DLBCL) confirmed by tumor histopathology with at least one lesion on either axis More than 1.5 cm, sufficient specimens for second-generation sequencing or single-cell sequencing; 2. Age \> 18 years old, \< 80 years old, gender unlimited; 3. EBER+ or peripheral blood EBV-DNA of pathological specimen was greater than 103copy/ml; 4. Patients judged by the investigator to have a life expectancy of at least 6 months; 5. The patient or his legal representative must provide written informed consent prior to any research special examination or procedure. 6. Signed written informed consent before screening.
Exclusion criteria
1. Have previously received systemic or local treatment including chemotherapy; 2. Previously received autologous stem cell transplantation; 3. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ; 4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases and serious infectious diseases; 5. Lymphoma involves the central nervous system; 6. Primary mediastinal large B-cell lymphoma; 7. Left ventricular ejection fraction \< 50%; 8. Laboratory test values at the time of screening: (unless due to lymphoma); 1. Neutrophils \< 1.5 x 109/L; 2. Platelet \< 75 x 109/L; 3. ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal; 4. creatinine levels higher than 1.5 times the upper limit of normal; 9. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol; 10. Pregnant or lactating women; 11. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection (polymerase chain Reaction \[PCR\] showed positive results). If the HbsAg test result is positive, HBV DNA test should be performed, if the HBV DNA\<103IU/ml, can be enrolled. If HBsAg test results are negative, but HBcAb test is positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\<103 IU/ml can be enrolled. If the patient's HCV antibody is positive, the HCV RNA is detected by PCR. If positive, the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival | 2 year |
Countries
China
Outcome results
None listed